Keller Postman is honored to help lead litigation in the Zantac federal multidistrict litigation. Contact Us for a Legal Consultation Why work with Keller Postman?
We will work to help you obtain justice and compensation. If you were diagnosed with cancer after consuming Zantac or generic ranitidine, you may qualify for legal action. The federal Zantac multidistrict litigation consolidates for pretrial purposes lawsuits accusing Pfizer Inc., Sanofi SA, Boehringer Ingelheim Pharmaceuticals Inc., and GlaxoSmithKline LLC-as well as generic makers, distributors, pharmacies, and others in the supply chain-of design defect, failure to warn, and other claims. Keller Postman represents individuals throughout the United States who took Zantac or a generic brand of ranitidine to treat heartburn and were later diagnosed with cancer. Although we wish we could reverse our clients’ tragic diagnoses, we are tirelessly fighting to hold the defendants-including brand and generic makers of the heartburn medication-accountable. The increased risk of cancer for consumers of Zantac is undeniable, and our team at Keller Postman is fighting hard for victims.
Drug manufacturers were aware of the risk but said nothing. NDMA is toxic-a chemical commonly used to cause cancer in lab rats and as an ingredient in rocket fuel. But one tablet of Zantac can contain up to 2.5 to 3 million nanograms of NDMA. NDMA exposure is safe if limited to 96 nanograms per day. The FDA confirmed that ranitidine contains unacceptable levels of NDMA and that the amount of NDMA increases when the medication is exposed to higher temperatures. Food and Drug Administration (FDA) asked all manufacturers to withdraw ranitidine products from the market after finding extremely high levels of the carcinogen n itrosodimethylamine (NDMA) in the ingredients of ranitidine medications-commonly known by the brand name Zantac.
0 kommentar(er)
